Observing the natural progression of RFC1 repeat expansion disease
Official title: RFC1 Natural History Study
Run by University Hospital Tuebingen · NCT05177809 · Data updated 2026-11-12
This study is trying to understand how RFC1 repeat expansion disease affects people over time and to find helpful markers for diagnosis and future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | University Hospital Tuebingen Academic / other |
| Locations | 10 sites (Melbourne, Victoria and 9 other locations) |
| Status | Recruiting |
| Started | December 14, 2021 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | March 31, 2026 |
| Trial ID | NCT05177809 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with a genetic diagnosis of bi-allelic pathogenic repeat expansions in RFC1.
✕Probably not a fit
Patients with evidence of neuropathy, neurodegenerative disease, or movement disorders, as well as those unable to provide informed consent, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This international, multi-center observational study aims to explore the phenotypic spectrum and natural progression of RFC1 repeat expansion disease, a form of ataxia that typically presents in late adulthood. Participants will undergo annual assessments that include standardized clinical examinations and optional biosample donations for biomarker analysis. The study will utilize a clinical database to track data and outcomes, while also potentially incorporating various additional examinations to capture the disease's multisystemic effects. The goal is to identify reliable biomarkers that can aid in diagnosis and serve as outcome measures for future clinical trials.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic tools and outcome measures for patients with RFC1 repeat expansion disease.
How similar studies have gone: While this study employs a novel approach to understanding RFC1 repeat expansion disease, similar observational studies have shown success in characterizing other genetic ataxias.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * RFC1: genetic diagnosis of bi-allelic pathogenic repeat expansions in RFC1 * Unrelated healthy controls: no signs or history of neurological or psychiatric disease AND * Written informed consent AND * Participants are willing and able to comply with study procedures Exclusion Criteria: * RFC1: Missing informed consent * Controls: evidence of neuropathy, neurodegenerative disease, or movement disorder; inability to give informed consent
Where it's running
-
Department of Neuroscience, Central Clinical School, Monash University
Melbourne, Victoria, Australia Recruiting -
Department of Neurology, Ataxia Unit, Universidade Federal de São Paulo
São Paulo, State of São Paulo, Brazil Recruiting -
Service de Neurologie, Hôpitaux Universitaires de Strasbourg
Strasbourg, Strasbourg, France Recruiting -
Center for Neurology & Hertie-Institute for Clinical Brain Research, Dept. for Neurodegenerative Diseases
Tübingen, Baden-Wurttemberg, Germany Recruiting -
German Center for Neurodegenerative Diseases (DZNE)
Bonn, North Rhine-Westphalia, Germany Recruiting -
Department of Neurology University Hospital Schleswig Holstein
Lübeck, Schleswig-Holstein, Germany Recruiting
Show 4 more locations
-
Università degli Studi di Napoli 'Federico II', c/o AOU Federico II
Naples, Napoli, Italy Recruiting -
IRCCS Fondazione Stella Maris
Pisa, Italy Recruiting -
Centre of Brain Research Neurogenetics Research Clinic, University of Auckland
Auckland, New Zealand Recruiting -
Koç University Hospital, KUTTAM-NDAL
Istanbul, Turkey (Türkiye) Recruiting
Study contacts
- Principal investigator: Matthis Synofzik, Prof. Dr. — University Hospital Tuebingen
- Study coordinator: Matthis Synofzik, Prof. Dr.
- Email: matthis.synofzik@uni-tuebingen.de
- Phone: +49 7071 29
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How foot braces might help people with ataxia walk better
This study tests whether wearing foot orthoses at home can improve gait and balance for adults with cerebellar ataxia.
-
Registry and natural history of epilepsy-dyskinesia syndromes
This registry will collect health data and biological samples from people of all ages who have a genetic diagnosis of epilepsy-dyskinesia syndromes to see how their genes relate to their movement and seizure symptoms over time.
-
Registry and biobank for neuroimmunological diseases
This study is trying to see if certain antibodies in the brain are linked to neurological disorders like encephalopathy and psychosis, and how they might affect patients' health.
-
Home-based training for improving gait and balance in movement disorders
This study is testing whether a three-week home training program can help people with movement disorders like ataxia and Parkinson's improve their balance and walking.
-
Understanding epilepsy-dyskinesia syndromes in children
This study is trying to learn more about epilepsy-dyskinesia syndromes in children by gathering information from different countries to see how these movement and seizure disorders are related.
-
Cerebellar tACS plus iTBS combined with exercise for ataxia balance
This test will see if combining cerebellar tACS and iTBS with guided exergaming improves balance in people with ataxia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.